
Cognyte Software Ltd. CGNT
$ 9.95
-0.4%
Annual report 2026
added 04-25-2026
Cognyte Software Ltd. Book Value 2011-2026 | CGNT
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Cognyte Software Ltd.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 229 M | 217 M | 215 M | 210 M | 299 M | 270 M | 455 M | - | - | 64 M | 63.2 M | 22.7 M | -14.5 M | -8.6 M | -449 K | 6.52 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 455 M | -14.5 M | 145 M |
Quarterly Book Value Cognyte Software Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 299 M | - | - | - | 270 M | - | - | - | 455 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 455 M | 270 M | 342 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
638 M | - | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
28 M | $ 11.2 | 0.27 % | $ 317 M | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 8.24 | 0.24 % | $ 1.24 B | ||
|
Aziyo Biologics
AZYO
|
27.7 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.25 | -1.62 % | $ 159 M | ||
|
BioSig Technologies
BSGM
|
133 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-12.2 M | $ 5.88 | 1.38 % | $ 70.3 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
301 M | $ 2.31 | 6.94 % | $ 50.9 M | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Cytosorbents Corporation
CTSO
|
5.9 M | $ 0.47 | -0.57 % | $ 29.2 M | ||
|
MiMedx Group
MDXG
|
257 M | $ 3.79 | 4.12 % | $ 560 M | ||
|
OrthoPediatrics Corp.
KIDS
|
347 M | $ 18.5 | 1.48 % | $ 434 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 73.71 | 1.08 % | $ 4.02 B | ||
|
Delcath Systems
DCTH
|
111 M | $ 11.23 | 3.5 % | $ 402 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
4.92 M | $ 1.0 | -4.76 % | $ 16.9 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Pulmonx Corporation
LUNG
|
54.1 M | $ 1.54 | 14.93 % | $ 62.7 M | ||
|
Electromed
ELMD
|
43.2 M | $ 37.74 | -1.64 % | $ 319 M | ||
|
Myomo
MYO
|
11.4 M | $ 0.91 | 4.17 % | $ 38.1 M | ||
|
Butterfly Network
BFLY
|
196 M | $ 4.39 | 6.94 % | $ 1.08 B | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
15.7 M | - | -0.97 % | $ 54.4 M | ||
|
Orthofix Medical
OFIX
|
450 M | $ 12.15 | 0.5 % | $ 481 M | ||
|
Sintx Technologies
SINT
|
2.93 M | $ 2.21 | 0.45 % | $ 6.13 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
Profound Medical Corp.
PROF
|
66.4 M | $ 6.92 | 2.82 % | $ 209 M | ||
|
Globus Medical
GMED
|
4.57 B | $ 84.03 | 5.13 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 156.59 | 1.28 % | $ 11 B | ||
|
CONMED Corporation
CNMD
|
1.03 B | $ 37.01 | 2.29 % | $ 1.15 B | ||
|
Inspire Medical Systems
INSP
|
781 M | $ 44.14 | 3.79 % | $ 1.3 B | ||
|
TransMedics Group
TMDX
|
473 M | $ 68.0 | 2.83 % | $ 2.31 B | ||
|
Integer Holdings Corporation
ITGR
|
1.75 B | $ 91.49 | 1.16 % | $ 3.18 B | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
10.3 B | $ 82.97 | 0.99 % | $ 48.5 B |